Weight-loss drugs fight it out

Share this article:

The battle of the bulge got bigger in the past week. First, Eisai announced Friday that it was adding 200 contract sales reps to tout the benefits of the prescription weight-loss drug Belviq. This means that 600 personnel will be able to talk to doctors about the benefits of the slimming drug, which, like competitor Qsymia by Vivus, works when accompanied by dietary and activity changes.

The enlarged sales force is expected to be active by July 1.

Then, Reuters reported Friday that generics maker Actavis wants to get into the Qsymia business and is using claims of invalid patents as part of its marketing application to make generics of the slimming drug, which has a 2020 patent expiration date attached to it.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.